Grant to Speed Ebola Drug Production

Researchers at the University of California, Davis, will explore ways to speed production of the Ebola drug Zmapp with a $200,000 rapid-response grant from the National Science Foundation.

Written byUniversity of California
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Developed by Mapp Biopharmaceutical Inc. of San Diego, in collaboration with the U.S. government and partners in Canada, Zmapp is a cocktail of antibodies produced in and extracted from whole tobacco plants. The UC Davis team, including plant scientists, molecular biologists and chemical engineers, will attempt to produce the antibodies from plant cells grown in bioreactors instead of in whole plants.

To continue reading this article, sign up for FREE to
Lab Manager Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.
Add Lab Manager as a preferred source on Google

Add Lab Manager as a preferred Google source to see more of our trusted coverage.

Related Topics

CURRENT ISSUE - January/February 2026

How to Build Trust Into Every Lab Result

Applying the Six Cs Helps Labs Deliver Results Stakeholders Can Rely On

Lab Manager January/February 2026 Cover Image